Sor102 Hot! Direct
): A well-validated target in IBD that promotes systemic and local inflammation.
Currently, many advanced therapies for UC require intravenous (IV) infusions or subcutaneous injections, which can be inconvenient and lead to systemic immunosuppression (side effects throughout the whole body). SOR102 offers several advantages: sor102
Please provide more details so I can assist you accurately. ): A well-validated target in IBD that promotes
Current biologic therapies typically target a single pathway, such as or IL-23 . While effective, many patients experience a loss of response over time. SOR102 changes the game by combining two humanized single-domain antibodies into one molecule: Anti-TNF Developed by Sorriso Pharmaceuticals
is an investigational, orally delivered biologic currently in clinical development for the treatment of inflammatory bowel disease (IBD), specifically ulcerative colitis (UC) . Developed by Sorriso Pharmaceuticals, it represents a potential paradigm shift in how advanced therapies are administered to patients with chronic gastrointestinal inflammation. What is SOR102?
Could you clarify which of these you mean?
